Most Recent Clinical Advances in CAR T Cell and Gene Therapy 2017/2018
Adoptive cell therapy with gene-engineered T cells bearing antitumor-reactive T-cell receptor or chimeric antigen receptor (CAR) is a promising and rapidly evolving field of translational medicine. This approach has delivered exciting responses for some patients with lymphoid hematologic neoplasms, leading to recent US Food and Drug Administration approvals. Hematopoietic stem cellular gene therapy has also shown promising advances, with durable and potentially curative clinical benefit and without the potential toxicities of allogeneic hematopoietic cell transplant. However, for both of these novel strategies, many questions remain unanswered. Compared to synthetic viral gene addition therapy (e.g., CAR T-cell engineering), translation of gene-editing technologies to patient care is in its infancy. Multiple clinical trials are ongoing or expected to open for CAR T cell and inherited monogenic disorders (Gardner et al., Blood 129:3322–3331, 2017) (refer to subsequent disease-specific chapters in the book). In this chapter, we will highlight the most recent and clinically relevant developments in the arena of gene-modified T-cell-based therapies and hematopoietic stem cellular gene therapy specifically focusing on hematologic disorders. We will conclude the chapter by summarizing the apparent challenges and directions for the future.
KeywordsCell therapy Gene therapy CAR T cell Lymphoma CLL ALL Leukemia CD19 Chimeric antigen receptors Adoptive T-cell therapy Chimeric antigen receptor-modified T cells
Conflict of Interest
Syed A. Abutalib—None.
Saar I Gill—Research funding (Novartis); Equity (Carisma Therapeutics); Scientific Advisory Board (Carisma Therapeutics, Extellia Therapeutics).
- Antony JS, Haque AKMA, Lamsfus-Calle A et al (2018) CRISPR/Cas9 system: a promising technology for the treatment of inherited and neoplastic hematological diseases. Adv Cell Gene Ther 1:e10. https://onlinelibrary.wiley.com/doi/abs/10.1002/acg2.10 CrossRefGoogle Scholar
- Berdeja JG, Lin Y, Raje N et al (2017) Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-Bcma CAR T cell therapy. Blood 130:740Google Scholar
- Brudno J, Lam N, Wang M et al (2017) T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor with a CD28 costimulatory moiety cause remissions of poor-prognosis relapsed multiple myeloma. Blood 130:524Google Scholar
- Buddee LB, Joo Y Song JY, Kim Y et al (2017) Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial. Abstract 811Google Scholar
- Buechner J, Grupp SA, Maude SL et al (2017) Global registration trial of efficacy and safety of CTL019 in pediatric and young adults patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): update of the international interim analysis. In: 2017 European Hematology Association (EHA) annual meeting (Abstract S476)Google Scholar
- Cohen AD, Garfall AL, Stadtmauer EA et al (2016) B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study. In: 58th American Society of Hematology annual meeting and exposition. Abstract #1147Google Scholar
- Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, Thrasher AJ, Armant M, Dansereau C, Lund TC, Miller WP, Raymond GV, Sankar R, Shah AJ, Sevin C, Gaspar HB, Gissen P, Amartino H, Bratkovic D, NJC S, Paker AM, Shamir E, O’Meara T, Davidson D, Aubourg P, Williams DA (2017) Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med 377(17):1630–1638CrossRefGoogle Scholar
- Fan F, Zhao W, Liu J et al (2018) Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. J Clin Oncol 35(18_suppl):LBA3001–LBA3001. https://doi.org/10.1200/JCO.2017.35.18_suppl.LBA3001 CrossRefGoogle Scholar
- Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129(25):3322–3331PubMedPubMedCentralGoogle Scholar
- Locke FL, Neelapu SS, Bartlett NL et al (2017b) Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (Axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Presented at 2017 AACR annual meeting; April 1–5, 2017; Washington, DC. Abstract CT019Google Scholar
- Santomasso BD, Park JH, Salloum D et al (2018) Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL). Cancer Discov 7:811Google Scholar
- Schuster S et al (2017b) Primary analysis of juliet: a global, pivotal, Phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. In: 59th American Society of Hematology annual meeting and exposition. Abstract #577Google Scholar
- Schuster SJ, Bishop MR, Tam C et al (2017c) Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) — an interim analysis. Hematol Oncol 35(Suppl 2):27. Abstract published June 7, 2017CrossRefGoogle Scholar
- Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG (2016) Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8(355):355ra116CrossRefGoogle Scholar